E. Eric Tokat
70 posts
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B Inhibrx, Inc. shareholders will receive $30/sh in cash, a $5 CVR, 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx prnewswire.com/news-releases/…
Ambrx to be acquired by Johnson & Johnson for $28/sh, or $2bn businesswire.com/news/home/2024…
$HARP Harpoon Therapeutics to be acquired by Merck $MRK for $23/sh, or $680M businesswire.com/news/home/2024…
$RYZB RayzeBio to be acquired by Bristol Myers Squibb for $62.50/sh, or $4.1bn $BMS news.bms.com/news/details/2…
$GRCL Gracell Biotechnologies to be acquired by AstraZeneca for $10+$1.50CVR, or up to $1.2bn $AZN ir.gracellbio.com/news-releases/…
AstraZeneca to acquire Icosavax for $15+$5; or up to $1.1bn $ICVX $AZN investors.icosavax.com/news-releases/…
AbbVie to acquire Cerevel Therapeutics for $45/sh, or $8.7bn investors.cerevel.com/news-releases/…
Roche to acquire Carmot Therapeutics for up to $3.1bn; or $2.7bn upfront plus $400M in Milestones carmot.us/carmot-therape…
Ajinomoto Co. to Acquire Forge Biologics for $620 Million forgebiologics.com/ajinomoto-co-i…
Lilly to acquire POINT Biopharma for $12.50/share, or $1.4bn $LLY $PNT investor.lilly.com/news-releases/…
